RxDoctor Payments DataLook up a doctor →

Nichole Pritchett, NP

Family · Centreville, ALNPI 1679954648

Payments from drug & device makers

$15,814in general payments, 2019–2025

Across 657 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Johnson & Johnson$2K
  • Novartis$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • Lilly USA, LLC$761
  • plus $4K from 17 others

What the payments were for

  • Consulting fees$2,00013%
  • Food & beverage$13,28784%
  • Education$5263%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,814 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$10,420
Medicare patients
58
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib54$414,866
Skyrizi PenRisankizumab-Rzaa13$263,574
Humira(Cf) PenAdalimumab25$249,142
Cosentyx Unoready PenSecukinumab17$128,261
Cosentyx Sensoready (2 Pens)Secukinumab11$79,869
OtezlaApremilast14$67,565
Dupixent SyringeDupilumab17$66,594
Clobetasol Propionate106$4,330
Tacrolimus28$3,411
Acitretin13$2,755
Fluocinolone AcetonideFluocinolone/Shower Cap32$2,089
Metronidazole26$1,889
Betamethasone Dipropionate60$1,854
Minocycline Hcl95$1,703
Fluorouracil23$1,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$5,816$414,86654 claims
AmgenOtezla$200$67,56514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Centreville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →